{
    "nctId": "NCT00461773",
    "briefTitle": "Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer",
    "officialTitle": "Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Hormone-Sensitive Breast Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Number of Patients With Objective Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed operable or potentially operable invasive breast adenocarcinoma that is clinically palpable and measurable\n* Age \u2265 18 years\n* Clinical Stage T2-4, N0-3, M0 (Stage II-III)\n* Postmenopausal defined as Age \u2265 60 years and/or Age \\>45 years with amenorrhea 12 months with an intact uterus and/or History of bilateral oophorectomy and/or FSH and estradiol levels in postmenopausal range\n* ECOG PS 0, 1\n* Unifocal disease\n* ER and/or PR positive\n* Adequate hematological, renal, and hepatic functions Absolute neutrophil count \u2265 1,500/\u00b5L Platelet count \u2265 100,000/\u00b5L creatinine \u2264 1.5 mg/dL Serum total bilirubin \u2264 1.5 mg/dL Alkaline phosphatase \u2264 3X the ULN for the reference lab SGOT/SGPT \u2264 3X the ULN for the reference lab\n* Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial\n* Use of effective means of contraception (men and women) in subjects of child-bearing potential\n\nExclusion Criteria:\n\n* Prior history of and/or therapy for invasive breast cancer (includes chemotherapy, radiation, hormonal therapy including AIs, tamoxifen, raloxifene, fulvestrant or any other antiestrogen/SERM)\n* Clinically significant cardiovascular disease, EF \\<50%\n* Known CNS disease\n* History of deep vein thrombosis or pulmonary embolism\n* Proteinuria at screening as demonstrated by either Urine protein:creatinine (UPC) ratio \u2265 1.0 at screening OR Urine dipstick for proteinuria \u2265 2+ (patients discovered to have \u22652+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \u2264 1g of protein in 24 hours to be eligible).\n* Presence of non-healing wound or fracture\n* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study\n* Inadequately controlled hypertension (defined as systolic blood pressure \\>150 and/or diastolic blood pressure \\> 100 mmHg on antihypertensive medications)\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)\n* History of myocardial infarction or unstable angina within 12 months prior to study enrollment\n* Any history of stroke or transient ischemic attack at any time\n* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)\n* Symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0\n* Core biopsy or other minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0\n* Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential is mandatory\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0\n* Known hypersensitivity to any component of bevacizumab or letrozole\n* Inability to comply with study and/or follow-up procedures",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}